Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

- Tezampanel Development Targeting Chronic Pain Conditions; Compound

Currently in Phase IIb Clinical Trial for Acute Migraine -

LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a Phase I multiple dose clinical trial to evaluate the safety, tolerability and pharmacokinetics of tezampanel given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. Tezampanel, an AMPA/kainate (AK) receptor antagonist that selectively binds to certain AK receptors to potentially block the transmission of pain signals, has been administered in single doses to more than 300 patients and healthy adults. Data from this multiple dose trial will support the continued development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider expanding the development of tezampanel into additional chronic pain conditions.

The double-blind, placebo-controlled, multiple-dose trial will be conducted at one center in the United States. Approximately 30 healthy male and female volunteers, between the ages of 21 and 55, will be enrolled in sequential, dose-escalating cohorts and receive once-daily subcutaneous doses of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days. These same dose strengths, given as a single dose subcutaneous injection, are currently being evaluated by TorreyPines in a Phase IIb clinical trial of tezampanel for acute migraine.

"We are pleased with our development progress for tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Sleep ... sleep therapy, and HGE Health Care Solutions, a ... announced today a comprehensive sleep management and cost ... (OSA). OSA is a chronic medical ... sleep and may increase a patient,s risk for ...
(Date:9/1/2015)... 1, 2015   Millstone Medical Outsourcing announced today ... in Olive Branch, MS. Now totaling ... facility has added the capacity required to meet the ... "This expansion gives us the opportunity to grow in parallel ... Millstone MS. "Two and a half years ago we were ...
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4
... in Ohio supported by the biopharmaceutical research sector would ... new taxes in the Medicare prescription drug program – ... to technical work, manufacturing to construction and other building ... sector supports a broad array of high-quality jobs. ...
... Sept. 27, 2011 Visiting Nurse Services of ... home health agencies, announces that it has entered ... advanced home telehealth technology to patients with chronic ... Experts in Telehealth(SM), is a world class developer, ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Visiting Nurse Services of Connecticut Selects Cardiocom® As Its New Telehealth Vendor 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... it is now offering the MonaLisa Touch® , an innovative vaginal health ... MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition that ...
(Date:9/1/2015)... ... ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation Hospital ... Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the Friends ... to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... firms and government entities, announced today that it has hired Scott Sanderson, an ... In this capacity, Sanderson will be responsible for establishing and managing new ...
(Date:9/1/2015)... ... September 01, 2015 , ... Zecurion, a leading developer of ... groundbreaking new version of endpoint DLP developed specifically for Mac OS. , In June ... than 100 IT and information security professionals had participated. The beta test done by ...
(Date:9/1/2015)... ... 01, 2015 , ... Two of Washington D.C.’s most respected chefs are using ... , Recently named “the next big thing” in the culinary world by Elle ... whole story behind food and reclaiming culinary traditions on the brink of extinction. According ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Zecurion Announces Endpoint Security for Mac 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... tumor cells can be lulled to sleep by a factor ... this week in the Journal of Experimental Medicine ... prostate cancer patients after treatment, often as a result of ... and colleagues at Southern Illinois University School of Medicine now ...
... PROVIDENCE, R.I. [Brown University] It,s no wonder that medicine,s ... arms race. When new drugs are developed to combat infections, ... A particularly ingenious weapon in the bacterial arsenal is the ... membranes of bacteria that can recognize and expel drugs that ...
... make use of recent experiences. Scientists from Ludwig-Maximilians-Universitt ... asked test subjects to estimate distances in a ... tended to approach the mean of all previously ... able to accurately predict the experimental findings using ...
... who have frequent bouts of wheezing with a daily dose ... But results of a recent study are likely to change ... at Washington University School of Medicine in St. Louis, found ... wheezing episodes than treating the child with higher doses of ...
... VOICE, an HIV prevention trial that has been evaluating ... HIV in women daily use of one of two ... stopped testing the gel. The decision to discontinue use of ... a routine review of study data concluded tenofovir gel was ...
... News) -- A condition called non-alcoholic fatty liver disease (NAFLD) ... new study finding that surprised Johns Hopkins researchers. It,s ... obesity and heart disease -- had a detrimental impact on ... does not affect survival. "Physicians have considered fatty liver ...
Cached Medicine News:Health News:New compound defeats drug-resistant bacteria 2Health News:New compound defeats drug-resistant bacteria 3Health News:When errors improve performance: Model describes how experiences influence our perception 2Health News:Daily wheezing treatment no different from intermittent in toddlers 2Health News:Daily wheezing treatment no different from intermittent in toddlers 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 2Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 4Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 5Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 6Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 7Health News:Fatty Liver Disease Doesn't Affect Survival, Study Finds 2
... The CSV-1000CVA20/30 test face provides three contrast ... acuity from 20/16 to 20/100. This test is ... such as associated with contact lens evaluation or ... of the test provide the same contrast and ...
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... Sample of Topics Covered: diagrams, ... tx's and differentials of a ... eyes, vision loss, pupillary abnormalities, ... infections, medications, cataracts, vision correction ...
Medicine Products: